Showing 4571-4580 of 5646 results for "".
- Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry AMD in Patients with High-Risk Genetic Variantshttps://modernod.com/news/gemini-therapeutics-completes-enrollment-in-phase-2a-trial-of-gem103-in-dry-amd-in-patients-with-high-risk-genetic-variants/2478851/Gemini Therapeutics announced the completion of enrollment in its phase 2a “ReGAtta” study. ReGAtta is a dose escalation trial of GEM103, a recombinant human complement factor H (CFH), in dry AMD patients with CFH loss-of-function gene variants. The trial is designed to evaluate safet
- Medicom Healthcare Signs Asset Purchase Agreement of Bimatoprost 0.3 mg/mL, 3mlhttps://modernod.com/news/medicom-healthcare-signs-asset-purchase-agreement-of-bimatoprost-0-3-mg-ml-3ml/2478852/Medicom Healthcare and Famar Health Care Services Madrid have announced the signing of an Asset Purchase Agreement (APA) for the acquisition by Medicom of the pharmaceutical dossier of Bimatorost 0.3 mg/mL, 3ml, preservative free eye drop solution, developed by Famar R&D. Under this agreement
- Johnson & Johnson Vision Celebrates 20 Years of See More Campaign and Global Patient Story Searchhttps://modernod.com/news/johnson-johnson-vision-celebrates-20-years-of-see-more-campaign-and-global-patient-story-search/2478846/Johnson & Johnson Vision announced a month-long celebration of the 20th Anniversary of the Tecnis platform, the proprietary combination of materials and design on which Johnson & Johnson Vision IOLs are built. Twenty years ago, a team of researchers and innovators created Tecnis, setting
- Roche Files for FDA Emergency Use Authorization for SARS-CoV-2 Rapid Antigen Testhttps://modernod.com/news/roche-files-for-fda-emergency-use-authorization-for-sars-cov-2-rapid-antigen-test/2478844/Roche announced it has submitted for FDA Emergency Use Authorization (EUA) for a SARS-CoV-2 Rapid Antigen Test that is designed for use by health care professionals in point-of-care settings with patients experiencing symptoms of COVID-19. The test is designed to help health care professi
- Santen Launches Ducressa Post-Cataract Surgery Antibiotic/Steroid Combinationhttps://modernod.com/news/santen-launches-ducressa-post-cataract-surgery-antibiotic-steroid-combination/2478828/Santen EMEA has announced the launch of Ducressa, a fixed dose combination of levofloxacin/dexamethasone eye drops solution indicated for the prevention and treatment of inflammation, and the prevention of infection a
- Turn Biotechnologies Expands the Potential of its mRNA Platform by Licensing Unique Artificial Niche Technologyhttps://modernod.com/news/turn-biotechnologies-expands-the-potential-of-its-mrna-platform-by-licensing-unique-artificial-niche-technology/2478826/Turn Biotechnologies announced that it has acquired the global rights for new artificial niche (AN) technology that can be used to restore muscle stem cells damaged by aging. Terms of the deal were not disclosed. The company licensed its AN technology from Stanf
- 2021 ASCRS Annual Meeting Moved to Las Vegas in Julyhttps://modernod.com/news/2021-ascrs-annual-meeting-moved-to-las-vegas-in-july/2478825/The American Society of Cataract and Refractive Surgery (ASCRS) announced that the 2021 ASCRS Annual Meeting, previously scheduled to take place in San Francisco in August, is now scheduled to be held July 23–27 in Las Vegas, Nevada, at the Mandalay Bay Convention Center. “Due to the
- Inflammasome Therapeutics Says Study Provides Human Data Confirming Potential of Company’s Proprietary Compounds for Prevention of Dry AMDhttps://modernod.com/news/inflammasome-therapeutics-says-study-provides-human-data-confirming-potential-of-companys-proprietary-compounds-for-prevention-of-dry-amd/2478824/Inflammasome Therapeutics reported that data analyses published in the current issue of Proceedings of the National Academy of Sciences (PNAS) confirms that the company’s proprietary compounds hold significant promise in the prevention and treatment of dry age-related macular degeneration
- Horizon Therapeutics to Acquire Viela Bio to Grow Rare Disease Medicine Portfoliohttps://modernod.com/news/horizon-therapeutics-to-acquire-viela-bio-to-grow-rare-disease-medicine-portfolio/2478819/Horizon Therapeutics and Viela Bio announced the companies have entered into a definitive agreement under which Horizon will acquire all of the issued and outstanding shares of Viela Bio common stock for $53 per share in cash, which represents a fully diluted equity value of approximately $3.05 b
- Ocutrx Technologies Appoints Bill Link, PhD, as Chairman of the Ocutrx International Scientific Advisory Boardhttps://modernod.com/news/ocutrx-technologies-appoints-bill-link-phd-as-chairman-of-the-ocutrx-international-scientific-advisory-board/2478813/Ocutrx Technologies has announced the appointment of William “Bill” Link, PhD, as the chairman of the Ocutrx International Scientific Advisory Board. The board plays a key role in guiding and prioritizing Ocutrx’s global research and development investment, while serving as the gu